Inotuzumab ozogamicin is deliverable in relapsed ALL patients with end-stage renal disease on hemodialysis.

Authors :: Amanam I
Ngo D
Pullarkat V
Aldoss I
Source :: Leukemia & lymphoma [Leuk Lymphoma] 2022 Dec; Vol. 63 (13), pp. 3268-3270. Date of Electronic Publication: 2022 Aug 25.
Publication Year :: 2022

Subjects :: Humans
Inotuzumab Ozogamicin
Sialic Acid Binding Ig-like Lectin 2
Renal Dialysis
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Kidney Failure, Chronic therapy

Full Text Access

Tools